Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (April 2025)
21 slides from Inoviq's investor presentation, Apr 3, 2025
Slide 1: Investor briefing: CAR-exosome therapeutic program
INOVIQ For personal use only investor briefing CAR-exosome therapeutic program 3rd April 2025 ASX: IIQ
Slide 2: Important notice and disclaimer
Important notice and disclaimer For personal use only This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. Th
Slide 3: INOVIQ overview: Next-generation diagnostics and therapeutics for cancer
INOVIQ overview| Next-generation diagnostics and therapeutics for cancer For personal use only Financial snapshot (ASX:IIQ) Market capitalisation A$46.3m Proprietary exosome platform with multiple research, diagnostic and therapeutic applications Share price (2 Apr 2025) A$0.415 52-week H/L A$0.80-0
Slide 4: Pipeline Priorities: Exosome diagnostics and therapeutics
Pipeline Priorities| Exosome diagnostics and therapeutics For personal use only Lead Products in Development 1. A screening test for Ovarian Cancer Specificity tells you how good a test is at correctly identifying women who do not have ovarian cancer. 4
Slide 5: Pipeline Priorities: Exosome diagnostics and therapeutics
Pipeline Priorities| Exosome diagnostics and therapeutics For personal use only Lead Products in Development 1. A screening test for Ovarian Cancer 2. A targeted treatment for Triple-Negative Breast Cancer (TNBC) Figure 1: Triple-negative breast cancer of left breast in 52-year-old woman. Uematsu T.
Slide 6: Pipeline Priorities: Allogeneic CAR-EV NK Therapy
Pipeline Priorities| Exosome diagnostics and therapeutics For personal use only Lead Products in Development Allogeneic CAR-EV NK Therapy A targeted treatment for Triple-Negative Breast Cancer (TNBC) natural immortalized reprogram grow killer cell cell bank exosome collect exosomes to CAR-EV NK Ther
Slide 7: Why focus on Triple-Negative Breast Cancer?
Why focus on Triple-Negative Breast Cancer? For personal use only • Unlike other breast cancer types there are no approved targeted treatments available • TNBC lacks the three most common drug targets for breast cancer treatment: estrogen receptor [ER], progesterone receptor [PR] and human epidermal
Slide 8: INOVIQ's approach is to develop a targeted treatment for TNBC
INOVIQ’s approach is to develop a targeted treatment for TNBC For personal use only The target … • EGFR protein on the surface of TNBC cells The therapeutic agent… • Cancer-killing exosome that targets EGFR- expressing TNBC cells • Targeting cancer cells is achieved by adding onto the surface of the
Slide 9: Exosomes: Significant diagnostic and therapeutic potential
Exosomes| Significant diagnostic and therapeutic potential For personal use only • Exosomes are tiny "packages" released by cells that DNA RNA help them communicate with each other. Cancer-killing Lipid • 200 times smaller than a cell: 100,000,000,000 per proteins bilayer ml of blood • They are like
Slide 10: Cancer-killing CAR-Exosomes: leveraging well established CAR-cell methods
Cancer-killing CAR-Exosomes | leveraging well established CAR-cell methods For personal use only CAR-EVs inherit the targeting and cytotoxic properties of their parent CAR-T or CAR-NK cells • CAR-EVs are produced by CAR-T/NK cells • CAR-EVs contains cytotoxic proteins (perforin, granzyme A,B,K FasL/
Slide 11: EGFR-targeting Exosomes: In vitro POC data
EGFR-targeting Exosomes| In vitro POC data For personal use only EGFR-targeting Exosomes (EVs) Immortalized NK cells EXO-ACE EGFR-targeting cells Isolate and enrich EVs NK cells successfully transduced with CAR-EVs isolated using proprietary CAR to target cancer cells technology for therapeutic use
Slide 12: CAR-NK-EVs: Planned in vitro study to evaluate anti-tumour efficacy
CAR-NK-EVs| Planned in vitro study to evaluate anti-tumour efficacy For personal use only Objective • Evaluate anti-tumour efficacy of CAR-EVs derived from immortalized human CAR-NK cells on triple negative breast cancer cells. Generation of CAR-NK cells CAR-NK cells CAR-EVs CAR-NK cells expansion m
Slide 13: CAR-NK-EVs: Planned in vivo study in mouse model
CAR-NK-EVs| Planned in vivo study to evaluate anti-tumour efficacy in mouse model For personal use only Objective • Evaluate anti-tumour efficacy of CAR-NK EVs on a TNBC – immunodeficient mouse model (CDX) CAR NK EVs CAR NK Cells Methods • NSG mouse model MDA-MB-231 • Evaluate dose and time effects
Slide 14: CAR-Exosomes: Allogeneic EV-based therapy with multiple advantages
CAR-Exosomes| Allogeneic EV-based therapy with multiple advantages For personal use only Engineer Establish In vivo Activate and In vitro Phase I/II immortalized Master Cell Isolate EVs animal IND expand efficacy Clinical Trials CAR-cells Bank studies ✓ Improved safety profile due to reduced GvHD (i
Slide 15: Cancer-killing Exosomes: Development path
Cancer-killing Exosomes| Development path For personal use only EXO-ACE In Vivo Selection First Patient CAR EV Isolation Studies of CRO Dose CAR-T / NK Cell In Vitro IND Regulatory Approval Development Studies Submission and Site Selection ✓Master cell ✓High purity & ✓In vitro PoC for ✓Peter Mac ban
Slide 16: Prof Phil Darcy: Peter Mac & INOVIQ Advisory Board member
Prof Phil Darcy| Peter Mac & INOVIQ Advisory Board member For personal use only • Co-leader of the Cancer Immunology program, Group Leader of the Cancer Immunotherapy Laboratory at the Peter MacCallum Cancer Centre and NHMRC Principal Research Fellow • Focused on novel T cell-based immunotherapy app
Slide 17: CAR-Exosome Therapy: Potent cancer killing and low toxicity
CAR-Exosome Therapy| Potent cancer killing and low toxicity For personal use only Off-the- • Next-gen cell-free therapy to target and kill solid tumours shelf, allogenic • Versatile and flexible technology platform with multiple Stabile & therapy Multiple therapeutic applications easier to therapeut
Slide 18: Dr Emma Ball: Chief Commercial Officer
Dr Emma Ball| Chief Commercial Officer (commences 7 April 2025) For personal use only • Experienced biotechnology commercialisation executive with expertise in business development, licensing, and strategic partnerships across therapeutics, vaccines and diagnostics • Non-Executive Chair of BioMelbou
Slide 19: Exosome Therapeutics market and drug candidates
Exosome Therapeutics market and drug candidates For personal use only Exosome therapeutics market Drug Company Indication Phase US$32.0m to $1.4b (2029-2040)1 CAP-1002 Capricor Therapeutics DMD Phase III 41.1% CAGR ExoFlo Direct Biologics ARDS Phase III BrainStorm Cell Debamestrocel ALS Phase III Th
Slide 20: Exosome & cell therapy deals
Exosome & cell therapy deals For personal use only Upfront Milestones Total Deal Value Acquirer / Licensee Target / Licensor Date Deal Type Stage Cell Source (US$m) (US$m) (US$m) 2024 Acquisition Phase 1 $1,038 $462 $1,500 T cell 2023 Acquisition Phase 1b $1,000 $200 $1,200 T cell Research Collabora
Slide 21: Q&A
Q&A For personal use only Dr Leearne Hinch BVMS MBA Prof Gregory Rice PhD MHA Chief Executive Officer Chief Scientific Officer e. lhinch@inoviq.com e. grice@inoviq.com Mark Edwards BAcc CA Dr Emma Ball PhD MBA GAICD CFO & Company Secretary Chief Commercial Officer e. medwards@inoviq.com e. eball@ino